Introduction {#Sec1}
============

Severe aortic stenosis (AS) is usually defined as an aortic valve area (AVA) \< 1.0cm^2^, mean transvalvular gradient (PG~mean~) ≥ 40 mmHg, and a peak flow velocity ≥ 4.0 m/s \[[@CR1]\]. Patients with AVA \< 1.0cm^2^ and PG~mean~\<40 mmHg are usually defined as low-gradient AS (LGAS). Further examinations are usually required to distinguish true-severe (TS) from pseudo-severe (PS) AS, which is clinically essential for therapeutic decision making because patients with TS-LGAS might benefit, whereas PS-LGAS patients might not benefit from aortic valve replacement (AVR) \[[@CR2]\]. LGAS is usually found in patients with reduced LV ejection fraction (LVEF \< 50%), but might also be present in patients with preserved LVEF ≥ 50% (so called paradoxical LGAS) \[[@CR3]\]. Low-dose dobutamine stress echocardiography (DSE) is recommended as a tool to define the severity of aortic stenosis in patients with LGAS and reduced LVEF \[[@CR4], [@CR5]\]. To date, data regarding the utility of DSE for defining severity of LGAS in patients with preserved LVEF presenting with either paradoxical low flow or normal flow remain scanty. In the present study, we observed if DSE could also be useful to define AS severity in LGAS patients with preserved LVEF. We further explored the conventional echocardiographic markers suggestive of TS-LGAS in LGAS patients with reduced or preserved LVEF.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

A total of 130 consecutive symptomatic low-gradient AS patients (aged 78 ± 8 years, 63.8% male), referred to the University Hospital Würzburg between January 2011 and December 2016, were included in this study. All patients underwent both standard transthoracic echocardiogram and DSE. Enrollment criteria included indexed aortic valve area (AVAi) ≤ 0.6 cm^2^/m^2^ and mean trans-aortic pressure gradient (PG~mean~) \< 40 mmHg as assessed by transthoracic echocardiogram. The study protocol is shown in Fig. [1](#Fig1){ref-type="fig"}. The study was conducted in accordance to the Declaration of Helsinki and was approved by the Local Ethics Committee at the University of Würzburg (AZ 11/03 and 60/14). Informed consent was obtained from all patients or their guardians.

Fig. 1A flow-chart of the study protocol. *LGAS* low gradient aortic stenosis, *AVAi* indexed aortic valve area, *PG*~*mean*~ mean trans-aortic pressure gradient, *LVEF* left ventricular ejection fraction, *TS* true-severe, *PS* pseudo-severe

Echocardiography {#Sec4}
----------------

Echocardiographic examination was performed with GE Vingmed Vivid 7 or E9, Horten, Norway. Standard measurements on cardiac structural and functional parameters were made according to the current ASE guideline \[[@CR6]\]. LV mass indexed to body surface area (LVMi) was calculated by the suggested formula \[[@CR7]\]. End-diastolic and end-systolic volumes and LVEF were measured with the biplane Simpson method in the apical 4- and 2-chamber views. Septal and lateral mitral annular plane systolic excursion (MAPSE) and tricuspid annular plane systolic excursion (TAPSE) were measured by M-mode in the apical 4-chamber view. Systolic pulmonary artery pressure (SPAP) was derived from peak tricuspid regurgitation jet velocity using the simplified Bernoulli equation, in combination with the estimated right atrial pressure. LV diastolic function was assessed according to ASE guidelines for the assessment of diastolic function \[[@CR8]\]. Tissue Doppler imaging was performed at the septal and lateral mitral annular sites enabling on-line derivation of myocardial systolic velocity (TDI-s′) and diastolic early velocity (e′) \[[@CR9]\]. Speckle tracking imaging analysis was performed using EchoPAC software (GE, Horten, Norway) as described previously \[[@CR10]\]. Longitudinal peak systolic strain (LS) of each segment was measured and global LS values were acquired by averaging strain rate and strain values of all 18 segments.

Evaluation of AS severity by standard echocardiography {#Sec5}
------------------------------------------------------

The diagnosis and classification of AS was made according to recent EAE/ASE recommendations \[[@CR11]\]. Left ventricular outflow tract (LVOT) diameter was measured in the parasternal long-axis view focusing on the LVOT at baseline, and this value was also used to calculate the aortic valve area during DSE. The outer edge of the velocity spectrum obtained by continuous wave (CW) Doppler across the aortic valve (AV) was traced to obtain the maximum velocity (V~max~), maximum and mean trans-aortic pressure gradient (PG~mean~ and PG~max~), and AV velocity time integral (VTI). The subvalvular V~max~ (LVOT V~max~), VTI and stroke volume (SV) were obtained by tracing the outer edge of the velocity spectrum at the LVOT by the pulsed wave (PW) Doppler. Aortic valve area by continuity equation VTI \[AVA (VTI)\] was automatically calculated using the formula: $$\documentclass[12pt]{minimal}
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Valvuloarterial impedance (Zva) was calculated using the formula:
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Low-dose dobutamine stress echocardiography {#Sec6}
-------------------------------------------

Dobutamine infusion was started at a dose of 5 µg/kg/min, then increasing to 10, 15, and 20 µg/kg/min at 3-min intervals. Blood pressure and heart rate were recorded at rest and at the end of each stage of dobutamine dosage. Contractile reserve was defined as an increase in stroke volume (SV) of 20% or more \[[@CR12]\]. The projected aortic valve area at normal transvalvular flow rate (AVA~proj~) was calculated using a simplified method with the following formula \[[@CR13]\]: Simplified AVA~proj~ = AVA~rest~ + VC~simpl~ × (250-Q~rest~), where VC~simpl~ is the valve compliance and Q was computed by dividing SV by LV ejection time. VC~simpl~ was computed with the formula:
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Follow-up {#Sec7}
---------

Patients were followed up for a mean of 18 (12--27) months by clinical visit or telephone interview.

Data analysis {#Sec8}
-------------

Continuous variables are presented as mean ± standard deviation or median (interquartile range, IQR), as appropriate. Normal distribution of all continuous variables was tested by inspecting skewness, kurtosis, and Q--Q plots. Clinical and echocardiographic continuous variables between preserved and reduced LVEF groups and between PS-LGAS and TS-LGAS groups were compared using independent Student´s t test or Mann--Whitney U test as indicated. Categorical variables were expressed as percentages and were compared using a Chi square test or Fisher's exact test, as appropriate. Multivariate logistic regression analysis was conducted to identify markers for differentiating TS-LGAS from PS-LGAS. Odds ratios (OR) with 95% confidence interval (CI) were assessed for indicating diagnostic performance. A two-tailed probability value \< 0.05 was considered significant. Statistical analysis was performed using IBM SPSS, version 23 for Windows (IBM Corp., New York, USA).

Results {#Sec9}
=======

Clinical characteristics {#Sec10}
------------------------

Patients were divided into two subgroups: LVEF ≥ 50% group (n = 63) and LVEF \< 50% group (n = 67). As shown in Table [1](#Tab1){ref-type="table"}, the proportion of male patients was significantly higher in the LVEF \< 50% group than in the LVEF ≥ 50% group (82.1% vs. 44.4%, P \< 0.001). Prevalence of NYHA class III-IV was documented in 79.1% of LVEF \< 50% patients and 55.5% of LVEF ≥ 50% patients (P = 0.003). The prevalence of diabetes (52.2% vs. 33.3%, P = 0.030) and coronary heart disease (71.6% vs. 49.2%, P = 0.009) was also significantly higher in the LVEF \< 50% group than in the LVEF ≥ 50% group.

Table 1Baseline clinical characteristicsTotalLVEF ≥ 50%LVEF \< 50%P valuen = 130n = 63n = 67Age (years)78 ± 879 ± 677 ± 80.117Male \[n (%)\]83 (63.8)28 (44.4)55 (82.1)\< 0.001BMI (kg/m^2^)27 ± 427 ± 427 ± 40.807NYHA class \[n (%)\]0.003 I10 (7.7)10 (15.9)0 (0) II32 (24.6)18 (28.6)14 (20.9) III75 (57.7)30 (47.6)45 (67.2) IV13 (10.0)5 (7.9)8 (11.9)Comorbidities \[n (%)\] Atrial fibrillation59 (45.4)28 (44.4)31 (46.3)0.835 Systemic hypertension114 (87.7)55 (87.3)59 (88.1)0.895 Diabetes mellitus56 (43.1)21 (33.3)35 (52.2)0.030 Obesity28 (21.5)16 (25.4)12 (17.9)0.299 Current smoking24 (18.5)9 (14.3)15 (22.4)0.234 Dyslipidemia68 (52.3)29 (46.0)39 (58.2)0.165 Coronary heart disease79 (60.8)31 (49.2)48 (71.6)0.009 CKD stage III-V80 (61.5)38 (60.3)42 (62.7)0.781 Respiratory disease35 (26.9)13 (20.6)22 (32.8)0.117 Malignancy18 (13.8)9 (14.3)9 (13.4)0.888 Stroke/TIA16 (12.3)9 (14.3)7 (10.4)0.506 Creatinine (mg/dl)1.15 (0.99--1.70)1.10 (0.93--1.53)1.27 (1.00-1.81)0.040 eGFR (ml/min/1.73qm)57 (39--74)57 (41--74)57 (36--72)0.633 C-reactive protein (mg/dl)0.48 (0.18--1.04)0.47 (0.14--0.97)0.53 (0.29--1.29)0.130Clinical outcomes Follow-up duration (months)18 (12 to 27)20 (12 to 30)16 (12 to 27)0.226 All-cause death \[n (%)\]28 (21.5)10 (15.9)18 (26.9)0.128 AVR/TAVI \[n (%)\]37 (28.5)/44 (33.8)19 (30.2)/22 (34.9)18 (26.9)/22 (32.8)0.813 OP within 30-days \[n (%)\]35 (43.2)18 (46.3)16 (40.0)0.565*BMI* body mass index, *NYHA* New York Heart Association, *CKD* chronic kidney disease, *eGFR* estimated glomerular filtration rate, *AVR* aortic valve replacement, *TAVI*, transcatheter aortic valve implantation

Baseline echocardiographic characteristics {#Sec11}
------------------------------------------

Mean LVEF was 60 ± 6% in the LVEF ≥ 50% group and 46 ± 4% in the LVEF \< 50% group (Table [2](#Tab2){ref-type="table"}). Patients with LVEF \< 50% had larger LV, RV and LA cavities, thicker LV walls, lower septal and lateral MAPSE and TAPSE as compared to patients with LVEF ≥ 50% (all P \< 0.05). AV Vmax, PG~mean~, LVOT V~max~, AV velocity ratio, and SV were significantly lower, while Zva was significantly higher in the LVEF \< 50% group than in the LVEF ≥ 50% group (all P \< 0.05). AVA VTI was similar between the LVEF LVEF ≥ 50% and \< 50% groups (0.86 ± 0.14 vs. 0.84 ± 0.16cm^2^, P = 0.538). LV longitudinal systolic function parameters including septal and lateral TDI-s´as well as global and regional longitudinal strain (LS) at the basal septum were significantly lower in the LVEF \< 50% group than that in the LVEF ≥ 50% group.

Table 2Baseline echocardiographic characteristicsTotalLVEF ≥ 50%LVEF \< 50%P valuen = 130n = 63n = 67LVEDD (mm)50 ± 745 ± 555 ± 6\< 0.001IVSd (mm)11.2 ± 1.310.7 ± 1.111.7 ± 1.3\< 0.001LVPWd (mm)10.8 ± 1.210.4 ± 1.011.2 ± 1.2\< 0.001LAD (mm)44 ± 643 ± 746 ± 420.002LVEF (%)47 ± 1560 ± 646 ± 4\< 0.001Septal MAPSE (mm)6.8 ± 2.58.2 ± 2.25.4 ± 1.9\< 0.001lateral MAPSE (mm)8.4 ± 3.110.2 ± 2.76.8 ± 2.4\< 0.001TAPSE (mm)16.5 ± 4.918.5 ± 4.614.6 ± 4.4\< 0.001RVD_basal (mm)35 ± 734 ± 737 ± 70.011RVD_mid (mm)31 ± 830 ± 832 ± 70.165RAA (cm^2^)20 ± 719 ± 721 ± 70.284E (cm/s)101 ± 37105 ± 4197 ± 310.238DT (ms)194 ± 83212 ± 88176 ± 740.013E′ (cm/s)5.0 ± 2.25.2 ± 2.14.9 ± 2.20.374E/E′21 ± 921 ± 1022 ± 80.354Diastolic function \[n (%)\]0.127 Normal1 (0.8)1 (1.6)0 Grade I34 (26.2)21 (33.3)13 (19.4) Grade II59 (45.4)28 (44.4)31 (46.3) Grade III36 (27.7)13 (20.6)23 (34.3)Moderate or severe MR \[n (%)\]33 (25.4)13 (20.6)20 (29.9)0.228Moderate or severe AR \[n (%)\]23 (17.7)11 (17.5)12 (17.9)0.946Moderate or severe TR \[n (%)\]37 (28.5)17 (27.0)20 (29.9)0.717SPAP (mmHg)43 ± 1743 ± 1843 ± 160.944LVOT (mm)22.4 ± 1.621.7 ± 1.423.1 ± 1.4\< 0.001AV V~max~ (m/s)3.4 ± 0.43.5 ± 0.33.3 ± 0.40.004AV PG~mean~ (mmHg)29.4 ± 6.131.0 ± 5.727.9 ± 6.20.003LVOT V~max~ (m/s)0.74 ± 0.140.82 ± 0.120.67 ± 0.12\< 0.001AV velocity ratio0.22 ± 0.040.24 ± 0.040.20 ± 0.04\< 0.001AVA_VTI (cm^2^)0.85 ± 0.150.86 ± 0.140.84 ± 0.160.538Indexed AVA_VTI (cm^2^/m^2^)0.45 ± 0.080.47 ± 0.070.44 ± 0.080.012SVi (ml/m^2^)34.6 ± 9.240.0 ± 9.229.5 ± 5.6\< 0.001Zva (mmHg/ml/m^2^)4.7 ± 1.44.2 ± 1.05.2 ± 1.5\< 0.001Septal TDI-s´ (cm/s)3.8 ± 1.34.4 ± 1.23.2 ± 1.0\< 0.001lateral TDI-s´ (cm/s)4.6 ± 1.55.2 ± 1.44.1 ± 1.5\< 0.001Longitudinal strain (%) GLS_4ch11.4 ± 4.814.9 ± 3.98.2 ± 2.9\< 0.001 GLS_2ch11.6 ± 4.714.7 ± 3.98.6 ± 3.2\< 0.001 GLS_3ch11.5 ± 4.814.7 ± 4.08.7 ± 3.4\< 0.001 GLS_average11.5 ± 4.514.7 ± 3.68.5 ± 2.8\< 0.001 Basal septal LS8.3 ± 4.010.1 ± 3.66.6 ± 3.6\< 0.001*LVEDD* left ventricular end-diastolic dimension, *IVSd* end-diastolic interventricular septal thickness, *LVPWd* end-diastolic left ventricular posterior wall thickness, *LVEF* left ventricular ejection fraction, *MAPSE* mitral annular plane systolic excursion, *TAPSE* tricuspid annular plane systolic excursion, *RVD* right ventricular dimension, *RAA* end-systolic right atrial area, *E* mitral inflow early filling velocity, *DT* deceleration time of early filling, *E*′ early diastolic mitral annular velocity, *E*/*E*′ the ratio between mitral inflow early filling velocity and mitral annular velocity, *MR* mitral regurgitation, *AR* aortic regurgitation, *TR* tricuspid regurgitation, *SPAP* systolic pulmonary artery pressure, *LVOT* left ventricular outflow tract, *AVA_VTI* aortic valve area calculated by the velocity time integral, *AV* aortic valve, *Vmax* maximum velocity by continuous-wave Doppler, *PG*~*mean*~ mean transvalvular pressure gradient, *SVi* stroke volume indexed to body surface area, *Zva*, valvuloarterial impedance; *TDI-s´* tissue-Doppler imaging derived mitral annular systolic peak velocity, *GLS* global longitudinal strain

DSE {#Sec12}
---

DSE results in the patients with LVEF ≥ 50% and LVEF \< 50% are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Forty-three out of 63 (68.3%) in the LVEF ≥ 50% group and 41 out of 67 (61.2%) patients in the LVEF \< 50% group were diagnosed as TS-LGAS by DSE. AV Vmax, PG~mean~, LVOT V~max~, AV velocity ratio, and AVA VTI significantly increased during DSE both in LVEF ≥ 50% and \< 50% groups (all P \< 0.05, Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}). Systolic blood pressure remained unchanged while peak diastolic blood pressure decreased in both groups during DSE.

Table 3Low-dose dobutamine stress echocardiographic characteristicsTotalLVEF ≥ 50%LVEF \< 50%P valuen = 130n = 63n = 67True-severe AS \[n (%)\]84 (64.6)43 (68.3)41 (61.2)0.400Pseudo-severe AS \[n (%)\]46 (35.4)20 (31.7)26 (38.8)LV flow reserve (ΔSV ≥ 20%) \[n (%)\]76 (58.5)32 (50.8)44 (65.7)0.085Rest SBP (mmHg)126 ± 21131 ± 21120 ± 200.002Peak SBP (mmHg)125 ± 28132 ± 29118 ± 250.007Δ SBP (%)0 (-- 14 to 12)-- 1 (-- 15 to 13)0 (-- 13 to 8)0.658Rest DBP (mmHg)66 ± 1366 ± 1365 ± 190.820Peak DBP (mmHg)58 ± 14\*58 ± 15\*58 ± 13\*0.739Δ DBP (%)-- 11 (-23 to 0)-- 8 (-- 21 to 0)-- 13 (-- 24 to 0)0.955Rest HR (beats/min)70 ± 1267 ± 1172 ± 120.006Peak HR (beats/min)92 ± 20\*94 ± 19\*91 ± 20\*0.385Δ HR (%)29 (13 to 50)40 (18 to 61)20 (9 to 44)0.001Rest LVEF (%)47 ± 1661 ± 834 ± 8\< 0.001Peak LVEF (%)58 ± 17\*71 ± 8\*45 ± 12\*\< 0.001Δ LVEF (%)24 (12 to 36)16 (8 to 25)34 (20 to 51)\< 0.001Rest LVSV (ml)68 ± 1774 ± 1662 ± 16\< 0.001Peak LVSV (ml)79 ± 20\*85 ± 20\*73 ± 19\*\< 0.001Δ LVSV (%)23 (3 to 41)20 (-- 2 to 38)27 (4 to 42)0.069Rest AV V~max~ (m/s)3.4 ± 0.43.5 ± 0.43.3 ± 0.30.001Peak AV V~max~ (m/s)4.2 ± 0.6\*4.4 ± 0.5\*4.0 ± 0.5\*\< 0.001Δ AV V~max~ (%)23 (11 to 32)27 (15 to 34)22 (8 to 32)0.148Rest PG~mean~ (mmHg)30 ± 632 ± 629 ± 60.003Peak PG~mean~ (mmHg)45 ± 12\*48 ± 11\*42 ± 12\*0.005Δ PG~mean~ (%)45 (22 to 67)48 (29 to 75)44 (19 to 66)0.685Rest LVOT V~max~ (m/s)0.7 ± 0.20.8 ± 0.10.7 ± 0.1\< 0.001Peak LVOT V~max~ (m/s)1.0 ± 0.3\*1.1 ± 0.2\*0.9 ± 0.2\*\< 0.001Δ LVOT V~max~ (%)34 (9 to 49)36 (14 to 52)25 (4 to 43)0.063Rest AV velocity ratio0.22 ± 0.040.24 ± 0.040.20 ± 0.04\< 0.001Peak AV velocity ratio0.24 ± 0.06\*0.25 ± 0.06\*0.22 ± 0.04\*0.001Δ AV velocity ratio (%)5 (-- 9 to 19)11 (-- 6 to 18)2 (-- 11 to 21)0.479Rest AVA_VTI (cm^2^)0.88 ± 0.180.89 ± 0.150.86 ± 0.210.301Peak AVA_VTI (cm^2^)0.98 ± 0.27\*1.04 ± 0.24\*0.92 ± 0.27\*0.009Δ AVA_VTI (%)11 (-- 2 to 28)15 (3 to 29)4 (-- 9 to 25)0.047Rest flow rate0.22 ± 0.050.24 ± 0.040.21 ± 0.050.003Peak flow rate0.33 ± 0.100.36 ± 0.100.30 ± 0.08\< 0.001Δ flow rate (%)46 (28 to 62)49 (33 to 71)45 (20 to 60)0.151AVA~proj~ (cm^2^)0.90 ± 0.190.89 ± 0.140.91 ± 0.250.588*SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HR* heart rate, *LVEF* left ventricular ejection fraction, *PG*~*mean*~ mean transvalvular pressure gradient, *SVi* stroke volume indexed to body surface area, *AVA_VTI* aortic valve area calculated by the velocity time integral, *LGSAS* low-gradient severe aortic stenosis, *LGMAS* low-gradient moderate aortic stenosis, *AVA*~*proj*~: projected aortic valve area at normal transvalvular flow rate\*P \< 0.05 vs. respective parameters at rest

Table 4DSE characteristics in patients with PS- and TS-LGAS patientsLVEF ≥ 50%LVEF \< 50%PS-LGAS\
(n = 20)TS-LGAS\
(n = 43)PS-LGAS\
n = 26TS-LGAS\
n = 41Rest AV V~max~ (m/s)3.5 ± 0.43.6 ± 0.43.3 ± 0.43.3 ± 0.3Peak AV V~max~ (m/s)4.2 ± 0.54.5 ± 0.5\*3.7 ± 0.44.2 ± 0.5\*Δ AV V~max~ (%)18 (13 to 31)29 (17 to 36)\*13 (2 to 24)26 (11 to 33)\*Rest PG~mean~ (mmHg)31 ± 732 ± 628 ± 629 ± 6Peak PG~mean~ (mmHg)43 ± 1150 ± 11\*35 ± 846 ± 12\*Δ PG~mean~ (%)39 (16 to 63)54 (36 to 77)30 (4 to 49)50 (28 to 84)\*Rest LVOT V~max~ (m/s)0.9 ± 0.10.8 ± 0.10.7 ± 0.10.6 ± 0.1\*Peak LVOT V~max~ (m/s)1.2 ± 0.21.1 ± 0.2\*1.0 ± 0.20.8 ± 0.2\*Δ LVOT V~max~ (%)38 (22 to 60)34 (11 to 50)36 (10 to 51)23 (3 to 41)Rest AV velocity ratio0.25 ± 0.040.23 ± 0.040.22 ± 0.030.19 ± 0.04\*Peak AV velocity ratio0.29 ± 0.050.24 ± 0.05\*0.26 ± 0.070.19 ± 0.04\*Δ AV velocity ratio (%)17 (5 to 26)4 (-- 12 to 16)\*14 (-- 2 to 36)-- 4 (-- 16 to 11)\*Rest AVA_VTI (cm^2^)0.97 ± 0.140.86 ± 0.14\*0.94 ± 0.220.81 ± 0.18\*Peak AVA_VTI (cm^2^)1.23 ± 0.240.96 ± 0.20\*1.12 ± 0.280.80 ± 0.19\*Δ AVA_VTI (%)20 (10 to 45)14 (-- 1 to 25)\*24 (-- 1 to 39)0 (-- 11 to 11)\*Rest septal MAPSE (mm)9.5 ± 2.27.9 ± 2.2\*5.2 ± 1.65.2 ± 1.6Peak septal MAPSE (mm)10.2 ± 2.79.2 ± 2.66.2 ± 2.36.2 ± 2.2Δ septal MAPSE (%)4 (-- 7 to 18)17 (0 to 33)17 (0 to 37)25 (0 to 50)Rest lateral MAPSE (mm)11.6 ± 2.29.8 ± 2.6\*7.1 ± 2.36.4 ± 2.4Peak lateral MAPSE (mm)12.8 ± 3.411.2 ± 2.79.5 ± 3.28.6 ± 3.3Δ lateral MAPSE (%)12 (0 to 27)12 (0 to 28)33 (9 to 61)37 (0 to 75)Rest TAPSE (mm)18.2 ± 3.917.9 ± 5.014.9 ± 4.914.0 ± 5.4Peak TAPSE (mm)18.8 ± 5.618.5 ± 5.316.4 ± 6.014.7 ± 5.5Δ TAPSE (%)5 (-- 19 to 23)0 (-- 8 to 17)12 (-- 8 to 20)8 (-- 8 to 18)Rest SPAP (mmHg)42 ± 1641 ± 1437 ± 1446 ± 15\*Peak SPAP (mmHg)55 ± 1654 ± 1543 ± 1757 ± 15\*Δ SPAP (%)30 (11 to 51)34 (12 to 54)15 (0 to 29)18 (10 to 40)AVA~proj~ (cm^2^)1.06 ± 0.040.84 ± 0.11\*1.21 ± 0.220.83 ± 0.19\*Abbreviations as shown in Table [3](#Tab3){ref-type="table"}\*P \< 0.05 vs. PS-LGAS

In the LVEF ≥ 50% group, baseline AVA_VTI (0.86 ± 0.14 vs. 0.97 ± 0.14 cm^2^, P = 0.007) and baseline MAPSE (septal: 7.9 ± 2.2 vs. 9.5 ± 2.2 mm, P = 0.009; lateral: 9.8 ± 2.6 vs. 11.6 ± 2.2 mm, P = 0.011) were significantly lower in the TS-LGAS subgroup than in the PS-LGAS subgroup. During DSE, AV velocity ratio was significantly increased in the PS-LGAS group (baseline 0.25 ± 0.04 vs. peak 0.29 ± 0.05, P \< 0.001), while remained unchanged in the TS-LGAS group (baseline 0.23 ± 0.04 vs. peak 0.24 ± 0.05, P = 0.531). AVA_VTI was significantly increased during DSE in the PS-LGAS group (baseline 0.97 ± 0.14 vs. peak 1.23 ± 0.24 cm^2^, P \< 0.001) and in the TS-LGAS group (baseline 0.86 ± 0.14 vs. peak 0.96 ± 0.20 cm^2^, P = 0.001).

In the LVEF \< 50% group, baseline AV velocity ratio (0.19 ± 0.04 vs. 0.22 ± 0.03, P = 0.006) and baseline AVA_VTI (0.81 ± 0.18 vs. 0.94 ± 0.22 cm^2^, P = 0.008) were significantly lower, while baseline SPAP (46 ± 15 vs. 37 ± 14 mmHg, P = 0.031) was significantly higher in the TS-LGAS group than in the PS-LGAS group. AV velocity ratio (baseline 0.22 ± 0.03 vs. peak 0.26 ± 0.07, P = 0.001) and AVA_VTI (baseline 0.94 ± 0.22 vs. peak 1.12 ± 0.28 cm^2^, P = 0.005) were significantly increased in the PS-LGAS group, while remained unchanged in the TS-LGAS group during DSE (AV velocity ratio: baseline 0.19 ± 0.04 vs. peak 0.19 ± 0.05, P = 0.352; AVA_VTI: baseline 0.81 ± 0.18 vs. peak 0.80 ± 0.19 cm^2^, P = 0.742).

All patients with baseline AVAi ≤ 0.3cm^2^/m^2^ were identified as TS-LGAS by DSE (n = 5). In the LVEF ≥ 50% group, 100%, 65.6% and 57.1% of patients with a baseline AVAi of 0.31--0.4, 0.41--0.5 and 0.51--0.6cm^2^/m^2^ were identified as TS-LGAS, respectively. In the LVEF \< 50% group, 78.9%, 65.5%, and 25.0% of patients with a baseline AVAi of 0.31--0.4, 0.41--0.5, and 0.51--0.6cm^2^/m^2^ were identified as TS-LGAS, respectively. Baseline AVAi ≤ 0.4cm^2^/m^2^ was highly suggestive of TS-LGAS in LGAS patients with LVEF ≥ 50% (specificity 100% and sensitivity 23%).

Significant mitral annular calcification (MAC) was found in 80 out of 130 (61.5%) patients. As shown in Fig. [2](#Fig2){ref-type="fig"}a, baseline septal MAPSE was significantly lower in the TS-LGAS group as compared to the PS-LGAS group in LVEF ≥ 50% patients without significant MAC (8.3 ± 2.1 vs. 10.5 ± 2.0 mm, P = 0.005). Lateral MAPSE was significantly lower in TS-LGAS group as compared to PS-LGAS group in LVEF ≥ 50% patients without (10.7 ± 2.4 vs. 12.3 ± 1.9 mm, P = 0.042) and with significant MAC (8.4 ± 2.2 vs. 10.5 ± 2.3 mm, P = 0.048; Fig. [2](#Fig2){ref-type="fig"}b).

Fig. 2Septal (**a**) and lateral (**b**) mitral annular plane systolic excursion (MAPSE) in low-gradient aortic stenosis (LGAS) patients with and without significant mitral annular calcification (MAC)

Echocardiographic markers suggestive of TS-LGAS {#Sec13}
-----------------------------------------------

Parameters, which are significantly associated with TS-LGAS with a statistic difference (p \< 0.05) between the PS-LGAS and TS-LGAS groups either in the subgroup of LVEF ≥ 50% or in the subgroup of LVEF \< 50% (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}), were tested in the multivariable binary regression models. Multivariable logical regression models (Table [6](#Tab6){ref-type="table"}) showed that baseline AVA_VTI was an independent determinant of TS-LGAS both in the LVEF ≥ 50% and \< 50% groups after adjusted for age and sex (LVEF ≥ 50%: OR 0.45, P = 0.004; LVEF \< 50%: OR 0.55, P = 0.005). Besides, lower septal and lateral MAPSE (adjusted OR 0.72--0.75, P = 0.013--0.016) as well as septal TDI-s´ (adjusted OR 0.53, P = 0.010) were significantly associated with TS-LGAS in patients with LVEF ≥ 50%. Higher SPAP and lower AV velocity ratio were associated with TS-LGAS in patients with LVEF \< 50% (SPAP: OR 1.43, P = 0.045; AV velocity ratio: OR 0.21, P = 0.035).

Table 5Baseline left ventricular longitudinal function characteristics in patients with PS- and TS-LGAS patientsLVEF ≥ 50%LVEF \< 50%PS-LGAS\
(n = 20)TS-LGAS\
(n = 43)PS-LGAS\
n = 26TS-LGAS\
n = 41Septal MAPSE (mm)9.5 ± 2.27.9 ± 2.2\*5.2 ± 1.65.2 ± 1.6Lateral MAPSE (mm)11.6 ± 2.29.8 ± 2.6\*7.1 ± 2.36.4 ± 2.4Septal TDI-s´ (cm/s)5.0 ± 1.34.1 ± 1.1\*3.3 ± 1.13.0 ± 0.9Lateral TDI-s´ (cm/s)5.5 ± 1.45.2 ± 1.44.1 ± 1.44.1 ± 1.6GLS (%)14.4 ± 3.614.9 ± 3.79.0 ± 2.58.3 ± 3.0Abbreviations as shown in Table [2](#Tab2){ref-type="table"}\*P \< 0.05 vs. PS-LGAS

Table 6Odds ratio of echocardiographic determinants for low-gradient severe aortic stenosisLVEF ≥ 50% (n = 63)LVEF \< 50% (n = 67)Age and sex adjusted OR95% CIP valueAge and sex adjusted OR95% CIP valueSeptal MAPSE (per 1 mm increase)0.720.56--0.930.0130.980.72--1.340.906Lateral MAPSE (per 1 mm increase)0.750.59--0.950.0160.920.74--1.150.473Septal TDI-s´ (per 1 cm/s increase)0.530.33--0.860.0100.730.44--1.210.219SPAP (per 10 mmHg increase)0.950.70--1.280.7321.431.01--2.040.045AVA_VTI (per 0.1cm^2^ increase)0.450.26--0.780.0040.550.36--0.830.005AV velocity ratio (per 0.1 increase)0.290.06--1.290.2860.210.05--0.900.035*CI* confidence interval, abbreviations as shown in Table [2](#Tab2){ref-type="table"}

Clinical Follow up results {#Sec14}
--------------------------

During follow-up, 28 (21.5%) patients died, 10 (15.9%) in LVEF ≥ 50% group \[3 with TS-LGAS (conservative therapy) and 2, 3, 7 with PS-LGAS (2 with conservative therapy, 3 surgical aortic valve replacement, and 2 transcatheter aortic valve implantation)\], and 18 (26.9%) in LVEF \< 50% group \[10 with TS-LGAS (6 conservative therapy, 1, 3, 8 surgical aortic valve replacement, and 3 transcatheter aortic valve implantation) and 8 with PS-LGAS (6 with conservative therapy, 1 surgical aortic valve replacement, and 1 transcatheter aortic valve implantation)\].

Discussion {#Sec15}
==========

The major findings of the present study are: (1) DSE appears to also be a helpful tool of defining true-severe low gradient aortic stenosis in patients with LVEF ≥ 50%; (2) Baseline AVA derived from transthoracic echocardiography is an independent determinant of TS-LGAS in both patients with LVEF ≥ 50% as well as LVEF \< 50%; (3) Reduced septal and lateral MAPSE as well as septal TDI-s´ are associated with TS-LGAS in patients with LVEF ≥ 50% while higher SPAP and lower AV velocity ratio are independently associated with TS-LGAS in patients with LVEF \< 50%.

Value of DSE in LGAS patients with reduced and preserved LVEF {#Sec16}
-------------------------------------------------------------

Patients with low gradient severe aortic stenosis (LGAS) and preserved LVEF (AVA \<1 cm^2^, PG~mean~ \<40 mmHg, LVEF \>50%) are increasingly recognised in clinical practice. DSE is recommended to define the severity of aortic stenosis in patients with LGAS and reduced LVEF \[[@CR4], [@CR5]\]. Our results showed that DES is also useful in defining TS- from PS-LGAS in patients with LVEF \< 50% (Table [4](#Tab4){ref-type="table"}). This finding is in line with a recent study, which demonstrated that DSE might serve as a valuable tool to distinguish TS-LGAS from PS-LGAS in patients with paradoxical LGAS \[[@CR14]\].

There were 20 out of 63 (31.7%) LGAS patients with preserved LVEF presenting with paradoxical low-flow LGAS (SVi ≤ 35 ml/m^2^) in our cohort. We compared other related parameters as well as the response on DSE between the two subgroups (low-flow vs. normal-flow LGAS). The data show that LV cavity in these patients was smaller than in patients with normal-flow LGAS (left ventricular end-diastolic dimension 43 ± 4 vs. 46 ± 5 mm, P = 0.021). Moreover, DSE seems also to be feasible to identify the TS-AS patients in the low-flow LGAS subgroup as in the normal-flow LGAS subgroup (Supplementary Table 1). Future studies with larger patient cohort are warrant to verify these results.

Echocardiographic determinant of TS-LGAS in patients with preserved LVEF {#Sec17}
------------------------------------------------------------------------

In line with previous findings from our group \[[@CR15]\] and others \[[@CR16]\], the present study results demonstrate that reduced MAPSE is suggestive of TS-LGAS in patients with LVEF \> 50%. A previous study also showed that MAPSE correlated with aortic valve area (Spearman *r* = 0.18, P = 0.02) in 205 asymptomatic AS patients with LVEF ≥ 50% \[[@CR17]\]. In another study, Rydberg and colleagues found that left atrioventricular plane displacement (MAPSE), but not left ventricular ejection fraction, was influenced by the degree of aortic stenosis \[[@CR16]\]. In patients with LGAS and preserved LVEF, LVEF is maintained at normal range at the expense of high LV end-diastolic pressure and volume. In this circumference, LV cannot recruit additional preload because the maximum sarcomere length is already reached and the hypertrophied stiff ventricle could not tolerate additional filling load \[[@CR18]\]. This might explain why reduced MAPSE, as a function of LV hemodynamic load, was revealed as the most sensitive marker of TS-LGAS in LGAS patients with LVEF \> 50%. Additionally, reduction in TDI-s´, another parameter reflecting LV longitudinal dysfunction, is also suggestive of TS-LGAS in AS patients with LVEF ≥ 50%.

Echocardiographic determinants of TS-LGAS in patients with reduced LVEF {#Sec18}
-----------------------------------------------------------------------

In LGAS patients with reduced LVEF, the disease features include both AS and heart failure. Ventricular remodeling (myocyte hypertrophy and myocardial fibrosis), systolic and diastolic dysfunction, in the setting of valvular stenosis and heart failure scenarios, contributes to the progressively elevated LV filling pressure, and/or left atrial pressure, which in turn would transmit to the pulmonary vasculature, inducing pulmonary venous congestion and pulmonary hypertension, so called WHO Group II - pulmonary hypertension \[[@CR19], [@CR20]\]. A previous study showed that pulmonary hypertension was presented in the majority of patients with severe aortic stenosis, and ejection fraction serves as one of the correlates of pulmonary hypertension in patients with severe aortic stenosis \[[@CR21]\]. Another study indicated that both smaller aortic valve area and lower LVEF were responsible for the presence of pulmonary hypertension in a cohort of 626 patients with severe aortic stenosis \[[@CR22]\]. In line with above findings, we found that increased systolic pulmonary pressure is an independent determinant of TS in LGAS patients with reduced LVEF. Another finding of the present study is that lower AV velocity ratio is related to the presence of true severe in LGAS patients with reduced LVEF. This parameter is only recommended in the EAE/ASE recommendations, a value of \< 0.25 is suggestive of severe AS \[[@CR23]\]. In our cohort, this value ranged from 0.23 at rest and 0.24 during DSE in TS-LGAS patients with LVEF \> 50%, and 0.19 at rest and 0.19 during DSE in TS-LGAS patients with reduced LVEF. A previous study reported that velocity ratios could not only define the severity of AS, but also predict outcomes in patients with TS-LGAS and preserved LVEF \[[@CR24]\]. Our results suggest AV velocity ratio could be used as an independent predictor for defining TS in LGAS patients with reduced LVEF.

Limitations {#Sec19}
===========

This retrospective study was performed monocentric and the number of patients included in the sub-cohorts was relatively small. The results of the present study might thus be affected by patient selection bias. Future studies with large patient cohort are warranted to validate the results obtained from this study. In this study, projected aortic valve area assessed by DSE was used to define the severity of AS \[[@CR25]\]. Other imaging modalities may aid in the diagnosis of severe AS. Macroscopic evaluation of the valve at the time of valve replacement or measurement of aortic valve calcium score by multislice computed tomography could provide additional accuracy to differ TS- from PS-AS \[[@CR26]\]. Due to the lack of available CT data for AV calcium score in our cohort, the severity of AS was only determined by projected aortic valve area. This study limitation should be considered in the interpretation of results derived from the current study.

Clinical implications {#Sec20}
---------------------

Our study results suggest that DSE enables evaluation of the severity of AS both in LGAS patients with reduced LVEF and in those with preserved LVEF, which is consistent with what has been demonstrated by previous studies \[[@CR13], [@CR26]\]. In the present study, we further explored the echocardiographic determinants suggestive of TS-LGAS. Reduced MAPSE and TDI-s´ are suggestive of TS in LGAS patients with preserved LVEF, while increased SPAP and lower AV velocity ratio are suggestive of TS in LGAS patients with reduced LVEF. These findings provide incremental information on the diagnosis and therapy decision for LGAS patients, particularly in those patients who cannot tolerate DSE due to the presence of contraindications. Patients with related echocardiographic features should be carefully evaluated for the AS severity with alternative complementary imaging modalities, such as measurement of aortic valve calcium score assessed by multislice computed tomography.

Conclusions {#Sec21}
===========

DSE is valuable for staging of LGAS in patients with both reduced and preserved LVEF. Low longitudinal LV function (MAPSE) and septal TDI-s´ are associated with TS-LGAS in patients with preserved LVEF, and high trans-tricuspid pressure gradient (SPAP) and low AV velocity ratio are associated with TS-LGAS in patients with reduced LVEF.
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